Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03459599
Other study ID # 16-1016-31034
Secondary ID
Status Completed
Phase N/A
First received February 23, 2018
Last updated March 8, 2018
Start date October 1, 2016
Est. completion date August 1, 2017

Study information

Verified date March 2018
Source Sarawak General Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In some centres, women are routinely given a course of antibiotics postnatally if ragged placental membranes were present at delivery. The investigators examined the necessity such an intervention.


Description:

Postpartum endometritis resulting in sepsis remain one of the leading cause of maternal mortality in developing countries. Ragged placental membrane is a risk factor for endometritis and is not infrequently encountered. Several hospitals in Malaysia, largely those geographically-removed currently practice administering prophylactic antibiotics for women with ragged placental membranes. The aim is to reduce the risk of postpartum endometritis in a subgroup of women who may present in dire straits. The investigators sought to examine the necessity of such protocols.


Recruitment information / eligibility

Status Completed
Enrollment 716
Est. completion date August 1, 2017
Est. primary completion date March 1, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

All women who delivered vaginally beyond 24+0 weeks of gestation and were found to have ragged or retained placental membranes immediately after the third stage of labour were invited to participate in the study.

Exclusion Criteria:

1. Fever, within 5 days preceding delivery (Axillary temperature > 37.5oC on 2 or more occasions at least 1 hour apart or temperature > 38oC on one occasion). This also includes intrapartum fever.

2. Required oral or intravenous antibiotics for any other obstetric-related (ex. third or fourth degree tears, preterm prelabour rupture of membranes) or non- obstetric related (ex. pneumonia, acute pyelonephritis) reasons

3. Prolonged rupture of membrane (>18 hours)

4. Retroviral disease, on long term oral or parenteral steroid or receiving other forms of immunosuppressants, including chemotherapy within the last one year.

5. Vaginal delivery for an intrauterine death

6. Penicillin allergy

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Prophylactic antibiotics
Amox-clav given to eligible women as per existing protocol, which is 625mg three times a day, for a week
Other:
No prophylaxis (Amox-clav withheld)
Withholding Amox-clav, which is the current local practice for women with ragged placental membranes. This was replaced with appropriate counselling on signs and symptoms of endometritis, when and where women should present if the symptoms above occur. A follow up phone call was performed at 2 weeks and 6 weeks postpartum to ascertain well-being of patients

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Sarawak General Hospital University Malaysia Sarawak

References & Publications (6)

Chibueze EC, Parsons AJ, Ota E, Swa T, Oladapo OT, Mori R. Prophylactic antibiotics for manual removal of retained placenta during vaginal birth: a systematic review of observational studies and meta-analysis. BMC Pregnancy Childbirth. 2015 Nov 26;15:313. doi: 10.1186/s12884-015-0752-4. Review. — View Citation

Chongsomchai C, Lumbiganon P, Laopaiboon M. Prophylactic antibiotics for manual removal of retained placenta in vaginal birth. Cochrane Database Syst Rev. 2014 Oct 20;(10):CD004904. doi: 10.1002/14651858.CD004904.pub3. Review. — View Citation

Fernandez H, Gagnepain A, Bourget P, Peray P, Frydman R, Papiernik E, Daures JP. Antibiotic prophylaxis against postpartum endometritis after vaginal delivery: a prospective randomized comparison between Amox-CA (Augmentin) and abstention. Eur J Obstet Gynecol Reprod Biol. 1993 Aug;50(3):169-75. — View Citation

Meaney-Delman D, Bartlett LA, Gravett MG, Jamieson DJ. Oral and intramuscular treatment options for early postpartum endometritis in low-resource settings: a systematic review. Obstet Gynecol. 2015 Apr;125(4):789-800. doi: 10.1097/AOG.0000000000000732. Review. Erratum in: Obstet Gynecol. 2015 Aug;126(2):452-3. — View Citation

Newton ER, Prihoda TJ, Gibbs RS. A clinical and microbiologic analysis of risk factors for puerperal endometritis. Obstet Gynecol. 1990 Mar;75(3 Pt 1):402-6. — View Citation

van Schalkwyk J, Van Eyk N; INFECTIOUS DISEASES COMMITTEE. Antibiotic prophylaxis in obstetric procedures. J Obstet Gynaecol Can. 2010 Sep;32(9):878-884. doi: 10.1016/S1701-2163(16)34662-X. Review. English, French. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of postpartum endometritis Postpartum endometritis is defined as follows, when presenting anytime within 6 weeks postpartum
Fever (Axillary temperature > 37.5 degrees Celcius on 2 or more occasions at least 1 hour apart or temperature > 38 degrees Celcius on one occasion), occurring in the absence of apparent source of infection or alternative foci of infection.
Increasing lochia loss or offensive lochia.
Lower abdominal pain or suprapubic tenderness on palpation.
The diagnosis is further supported by the following:
Elevated total white cell count > 11.0 x 109 cells/L
Positive genital swab culture.
Incidence is calculated as follows:
Number of patients diagnosed with endometritis in each arm/total number of patients allocated to each arm
6 weeks postpartum
Secondary ICU admission rate ICU admission as a result of endometritis. It is measured as follows:
a. ICU admission rate in prophylactic antibiotic group= (Number of patients requiring ICU admissions and given antibiotic prophylaxis, regardless of duration/total number of patients given antibiotics prophylaxis )
a. ICU admission rate in "no prophylaxis" group
= (Number of patients requiring ICU admissions and NOT given antibiotic prophylaxis, regardless of duration/total number of patients NOT given antibiotics prophylaxis)
6 weeks postpartum
Secondary Rate of surgical evacuation of retained products of conception Surgical procedure required as a result of ragged placental membrane or its complications. It is calculated as follows
Surgical evacuation of retained products of conception in prophylaxis group= (Number of patients requiring surgical procedure and given antibiotic prophylaxis, regardless of duration/total number of patients given antibiotics prophylaxis )
Surgical evacuation of retained products of conception in "no prophylaxis" group= (Number of patients requiring surgical procedure and NOT given antibiotic prophylaxis, regardless of duration/total number of patients NOT given antibiotics prophylaxis )
6 weeks postpartum
Secondary Rate of Blood transfusion Pack cell transfusion required as secondary to a complication from ragged placental membranes. This can be due to postpartum endometritis or surgical evacuation. It is calculated based on the number of patients requiring transfusion. The number of pack cells required per patient would be also be described.
Blood transfusion in prophylaxis group= (Number of patients requiring pack cell transfusion and given antibiotic prophylaxis, regardless of duration/total number of patients given antibiotics prophylaxis )
Blood transfusion in "no prophylaxis group"= (Number of patients requiring pack cell transfusion and were NOT given antibiotic prophylaxis, regardless of duration/total number of patients NOT given antibiotics prophylaxis )
6 weeks postpartum
See also
  Status Clinical Trial Phase
Recruiting NCT05049395 - HFNO Reducing the Incidence of Hypoxia for Hysteroscopy Sedated With Propofol N/A
Terminated NCT00386477 - Vaginal Cleansing at Cesarean Delivery to Reduce Infection: A Randomized, Controlled Trial N/A
Terminated NCT04163679 - Vaginal Preparation and Azithromycin to Reduce Post Cesarean Infections N/A
Recruiting NCT03960970 - Two-drug Antibiotic Prophylaxis in Scheduled Cesarean Deliveries Phase 2
Completed NCT01762098 - Chronic Endometritis in Patients With Recurrent Miscarriages or Repeated Implantation Failures in In-vitro Fertilization N/A
Withdrawn NCT01721616 - Comparison Study of Cefazolin Versus Cefazolin Plus Azithromycin Prophylaxis in Post-Cesarean Endometritis Phase 4
Completed NCT01464840 - The Pharmacokinetics of Azithromycin Prophylaxis for Cesarean Delivery N/A
Completed NCT01235546 - Study of Effectiveness and Safety of Azithromycin-based Extended-spectrum Prophylaxis to Prevent Post Cesarean Infection N/A
Recruiting NCT04307069 - Management of Prelabor Rupture of the Membranes at Term N/A
Terminated NCT01587495 - Pharmacokinetics and Safety of Ertapenem in the Postpartum Period Phase 1
Completed NCT03442218 - Use of Antiseptic Solution for Vaginal Wash Before Cesarean Section N/A
Not yet recruiting NCT01945450 - Prophylactic Antibiotics for Manual Removal of Retained Placenta in Vaginal Birth: a Randomized Controlled Trial N/A
Completed NCT00547170 - Doxycycline Prophylaxis at Vacuum Aspiration Trial Phase 4
Completed NCT00501033 - A Prospective Comparative Study of Induction of Labor With a Cervical Ripening Double Balloon vs Foley Catheter N/A
Completed NCT00500019 - Uterine Flora During Elective and Urgent Cesarean Sections N/A
Completed NCT00330278 - Timing of Prophylactic Antibiotics for Cesarean Sections N/A
Completed NCT00603603 - Controlled Clinical Trial of Supplemental Oxygen for the Prevention of Post-Cesarean Infectious Morbidity N/A
Completed NCT00858832 - Reduction of Endometritis After Cesarean Section With the Routine Use of Methergine N/A
Recruiting NCT04197167 - Mid-Infrared Spectroscopy as a Real Time Diagnostic Tool for Chronic Endometritis N/A
Completed NCT02402907 - STRIPES Study: Study To Reduce Infection Post cEsarean Section N/A